Multiple Myeloma Therapeutics - US Market Trends & Analysis

Published by	BizAcumen, Inc.
Published	November, 2009	Product code	104312
Content info	Pages: 347
Price	US $ 2995 PDF by E-mail (Single user license) US $ 8985 PDF By E-mail (Global License to Company and its Fully-owned Subsidiaries)

Introduction
Related Reports

Multiple Myeloma Therapeutics - US Market Trends & Analysis published by BizAcumen, Inc. in November, 2009. This report consists of Pages: 347 and the price starts from US $ 2995.

Introduction

Abstract

Given the severity, and relentless relapses of the disease, the push to develop efficient therapies and treatments to battle the disease and improve patient survival rates and quality of life, has been especially strong. Unfazed research and development activities, have over the years, resulted in commendable advances in treatment therapies and procedures. Although patients today have a broader choice of treatments than before, the objective of all the treatment therapies is to slower the growth of malignant myeloma cells rather than elimination, and offer palliative care such as, reduction in disease symptoms, such as, fatigue, anemia, bone pain, and recurrent infections, among others.

These and other market data and trends are presented in "Multiple Myeloma Therapeutics: US Market Trends & Analysis" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

1. METHODOLOGY

Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level

2. MARKET OVERVIEW

Hematological Cancer Therapies: A Prelude
- Treatment Regimes: The Golden Rule
Multiple Myeloma: A Second Most Common Hematological Cancer
Treatment Therapies: Move Up the Learning Curve
- Risk-Adapted Therapy: The New Norm of Future Treatment
- New Generation Drugs in the Arsenal Against Multiple Myeloma
  - Velcade® (Bortezomib)
  - Thalomid® (Thalidomide)
  - Revlimid® (Lenalidomide)
  - Alkeran (Melphalan)
  - Doxil (Liposomal Doxorubicin)
  - Trisenox® (Arsenic trioxide)
- Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons
  - Revlimid Overtakes Thalomid: Why?
  - How Effective Will Thalomid Be in the 3rd Line Setting? Skepticism Overflows
  - Revlimid Impedes Stem Cell Harvesting!!: What' s the Truth?
  - 1st & 2nd Generation Geldanamycin Analog to Do Wonders for Myeloma Treatment
Other Trends & Issues
- Approval of New Generation Drugs Push the Market Into the Bulge Bracket
- Growth Fundamentals Get Stronger
- Multidrug Resistance: A Challenge to Reckon With
- Gene Therapy Exudes Hope
- Challenges Encountered in Clinical Trials
- FDA' s Antidotes
- Europe Lagging Behind in Drug Approvals
- Market Share Statistics
  - Oncology and Hematology Market
- Drugs Approved & In Pipeline: A Review
  - Multiple Myeloma Drugs Approved by the FDA As of the Year 2008
  - Multiple Myeloma Drugs in Pipeline in the US As of the Year 2008
    - Phase III Drugs in Pipeline
    - Phase II Drugs in Pipeline
    - Phase I Drugs in Pipeline
- Key Non-Profit Organizations in the US
  - Multiple Myeloma Research Foundation (MMRF)
  - National Coalition for Cancer Survivorship (NCCS)
  - National Marrow Donor Program (NMDP)
  - Oregon Health and Science University Cancer Institute

3. PRODUCT FACTS

Drugs
Lines of Treatment

4. CORPORATE DEVELOPMENTS

NICE Grants Approval for Use of Revlimid®
SWOG Announces Closure of Phase III Trial (S0232) for Paitents with Multiple Myeloma
CytRx to Acquire Innovive
Launch of Epoetin alfa Hexal
PDL and Bristol-Myers Signs Agreement
MNKD and LLS Conclude Joint Research Agreement
MorphoSys and DSM Enter into Agreement
StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals in India
ImmunoCellular Acquires Molecular Antibody Technology
US House of Representatives Sanction the Hematological Cancer Research Investment and Education Act
Bayer and Cell Therapeutics Enter into Mutual Agreement
Bristol-Myers to Take Over Kosan Biosciences
Bristol and PDL BioPharma Enter into Agreement
Gamida Cell Enters Into a Agreement with Amgen
Circadian Acquires Complete Stake in Vegenics
Takeda Acquires Millennium Pharmaceuticals
Fujimoto Pharmaceutical Receives Approval to Market Thalidomide
Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug
FDA Grants Orphan-Drug Designation to Melphalan
Merck Commences Phase II-b and Phase III Clinical Trial of Zolinza
Clavis Initiates Phase II Trial of Elacytarabine
Gilead Sciences Commences GS 9219 Phase I Clinical Trial
AstraZeneca Carries Out AZD 0530 Phase II trial
European Commission Grants Approval of Thalidomide for Multiple Myeloma
EMEA Issues Positive Opinion for Thalidomide Use in Multiple Myeloma
Global Regulatory Developments for the Use of Revlimid® in Multiple Myeloma
Takeda Gains FDA Approval to Promote Velcade
Health Canada Approves VELCADE
Genzyme Receives FDA Certification for Mozobil
Celgene' s Thalidomide Pharmion Receives Marketing Authorization
GlaxoSmithKline Forms Alliance with OncoMed for Developing Cancer Therapeutics
Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals
Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer Drug
Aegera Therapeutics Acquires LymphoSign Inc
Velcade Gains Subsidy
Inex Pharmaceuticals Spins Off Biotechnology Business into Tekmira Pharmaceuticals
MilleGen Enters into Collaboration with LFB
Access Pharmaceuticals to Acquire Somanta
TopoTarget to Acquire Apoxis SA
Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics
Celgene Agrees to Acquisition of Pharmion
PerkinElmer Plans Acquisition of ViaCell
Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa
Johnson & Johnson Secures Contract worth US$112 Million
Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi Biopharmaceuticals
Ziopharm Commences Phase II Clinical Trial of ZIO-101
FDA Approves Pluristem' s Pre-IND Application of PLX-I
Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor
Swissmedic Approves Celgene' s REVLIMID Oral Cancer Drug
Celgene' s REVLIMID Receives EU' s Marketing Authorization
FDA Approves Application of Piramal' s IND-P276 Multiple Myeloma Drug
Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade® Phase II Trial
FDA to Consider the New Drug Application Filed for Use of Doxil® Combined with Velcade® in Patients with Multiple Myeloma
Ortho Biotech Files Application with FDA for Approval of Combination Drug DOXIL® and VELCADE®
Caraco' s Allopurinol Receives FDA Approval